Oncology
Pulmonary Neuroendocrine Tumor
5
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Pulmonary Neuroendocrine Tumor is an early-stage landscape with 5 programs across 3 companies. The most active players are Bristol-Myers Squibb, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Novartis. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 3
No programs
Analysis
Trial Status
4
clinical trials
Completed1 · 25%
Recruiting1 · 25%
Not yet recruiting1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
Not yet recruiting·—·Phase 2·NCT06764368·39 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)